Exhibit 99.1 FOR IMMEDIATE RELEASE Compugen Reports Fourth Quarter and Full Year 2023 Results • Partnership with Gilead on preclinical immuno-oncology program further validates Compugen’s computational discovery, research, and development capabilities • Catalyst rich 2024 expected with multiple data readouts and updates planned from Compugen’s diversified portfolio • Solid balance sheet with extended cash runway expected to fund operations into 2027 HOLON, ISRAEL, March 5, 2024 - Compugen Ltd. (Nasdaq: CGEN ...